Phaseline

Companies › MavriX Bio

MavriX Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MVX-220
AAVhu68 viral vector delivering UBE3A gene
UBE3APhase 1Angelman SyndromeMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07181837MVX-220Phase 1Angelman SyndromeOtherMar 2028

Targets

UBE3A (1)

Companies with the same targets

Ionis Pharmaceuticals OHB Pediatrics Ultragenyx Pharmaceutical

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.